MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Director's Dealing 2017

Oct 15, 2017

==> picture [563 x 81] intentionally omitted <==

16 October 2017

ASX ANNOUNCEMENT

Strong demand for Medical Developments Shares.

Medical Developments International Ltd (ASX: MVP) advise that its Chairman, Mr. David Williams sold 4.35 million MVP shares to 9 global and local financial institutions in the United Kingdom, the United States of America, Hong Kong and Australia in an off-market transaction on Thursday at $5.40 per share.

MVP Chairman Mr. David Williams said: “There is significant built up demand from a large number of leading financial institutions around the world for MVP shares. As Chairman and the company’s biggest shareholder I am very aware of the requirement to provide liquidity and maintain an appropriate capital structure for MVP. I am delighted and proud of the progress MVP has made and I believe this liquidity event will improve the chances of MVP’s shares appreciating in value in the short term.”

MVP CEO Mr. John Sharman said: “We are delighted with the confidence shown in MVP by the global investment community. MVP is gaining momentum in terms of its ambition to become a global pharmaceutical and medical device company. We have a number of milestone events which we hope to deliver during the latter part of this year and during the first quarter of 2018. We hope the achievement of these milestones will be reflected in the value of our company in the future.”

Enquiries: John Sharman Chief Executive Officer Medical Developments International Ltd 03 9547 1888

David Williams Chairman Medical Developments International Ltd 0414 383 593

Medical Developments International Limited ABN 14 106 340 667 4 Caribbean Drive Scoresby Victoria 3179 Australia Postal Address PO Box 9004 Scoresby Victoria 3179 Australia Telephone +61 3 9547 1888 Fax +61 3 9547 0262 Web www.medicaldev.com

==> picture [563 x 81] intentionally omitted <==

About Penthrox

Penthrox is a non-opioid, non-addictive, inhaled analgesic indicated in Australia for pain relief by selfadministration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used for more than 40 years in Australia and is now sold into 16 countries with circa 6.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, an analgesic product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

Medical Developments International Limited ABN 14 106 340 667 4 Caribbean Drive Scoresby Victoria 3179 Australia Postal Address PO Box 9004 Scoresby Victoria 3179 Australia Telephone +61 3 9547 1888 Fax +61 3 9547 0262 Web www.medicaldev.com